CRISPR-Cas13a Diagnostic System for High-Sensitivity Nucleic Acid Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid detection methods face challenges in achieving high sensitivity and specificity while being cost-effective and suitable for point-of-care settings, often requiring complex instrumentation or sacrificing sensitivity for portability.
Innovation Solution
A nucleic acid detection system utilizing a CRISPR system comprising an effector protein, guide RNAs, and signal amplification CRISPR effector proteins, along with RNA-based masking constructs, to detect target molecules with high specificity and sensitivity, potentially integrated into portable platforms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If qPCR approaches are used for nucleic acid detection, then sensitivity is improved, but device complexity and cost increase due to expensive instrumentation and complex operation requirements
Solution Approach 1:
The patent replaces complex mechanical/optical instrumentation systems (qPCR machines) with a biochemical system based on CRISPR-Cas13a complex. The detection mechanism shifts from thermal cycling and fluorescence measurement requiring expensive equipment to an isothermal reaction producing visible color changes detectable by simple means, thereby eliminating the need for complex instrumentation while maintaining high sensitivity
Solution Approach 2:
The patent employs disposable, pre-prepared CRISPR detection complexes and colorimetric reagents that can be used in single-use test devices. These disposable components eliminate the need for expensive, reusable instrumentation, making high-sensitivity detection accessible through simple, low-cost devices that can be discarded after use
2Ease of operation
If isothermal nucleic acid amplification with portable platforms is used, then ease of operation and portability are improved, but detection sensitivity decreases
Solution Approach 1:
The patent creates a composite detection system combining isothermal amplification (RPA) with CRISPR-Cas13a complex and colorimetric reporters. This composite approach integrates the portability and ease of operation of isothermal methods with the high sensitivity of CRISPR detection, achieving both goals simultaneously through synergistic combination of multiple biochemical components
Solution Approach 2:
The patent introduces CRISPR-Cas13a complex as an intermediary between the isothermal amplification step and the final detection step. The Cas13a complex acts as a mediator that amplifies the signal from the isothermal reaction through its collateral RNA cleavage activity, thereby enhancing sensitivity without compromising the portability and simplicity of the isothermal approach
3Reliability
If conventional nucleic acid detection methods are used, then detection capability is achieved, but loss of time occurs due to lengthy procedures
Solution Approach 1:
The patent implements continuous, isothermal amplification followed by continuous CRISPR-mediated signal amplification without interruption or thermal cycling. The reaction proceeds continuously in a single step, eliminating time losses associated with thermal cycling, sample preparation, and multiple processing stages, thereby achieving rapid detection while maintaining high reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system enables rapid, sensitive, and specific detection of nucleic acids, addressing the limitations of existing methods by providing a cost-effective and portable solution for diagnosing diseases and monitoring biological information.
Implementation Method 1
an effector protein, one or more guide RNAs designed to bind to corresponding target molecules
Implementation Method 2
one or more signal amplification CRISPR effector proteins
Data Source
AI summary
The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect both DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.